Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders

Neuropsychopharmacology

Volumn 42, Issue 6, 2017, Pages 1179-1181

  Sanacora, G ^a   Heimer, H ^b   Hartman, D ^c   Mathew, S J ^d,e   Frye, M ^f   Nemeroff, C ^g   Robinson Beale, R ^h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cure Alliance for Mental Illness   (United States)

^c Ketamine Advocacy Network   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h Blue Cross   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

HUMAN; MOOD DISORDER; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESISTANT DEPRESSION;

EID: 84991030713     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.193     Document Type: Note

References (7)

1. Advisory Council on the Misuse of Drugs (2013). Ketamine: A review of use and harm. Available at: Https://www. gov. uk/government/uploads/system/uploads/attachment-data/file/264677/ACMD-keta mine-report-dec13. pdf. Accessed 10 December 2013.
2. Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22: 238-249.
3. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aanhet Rot M et al (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250-256.
4. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB et al (2015). Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 172: 950-966.
5. Sanacora G, Schatzberg AF (2015). Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders Neuropsychopharmacology 40: 259-267.
6. Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P et al (2016). A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173: 816-826.
7. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481-486. Commentary 1181